Home data presentation
 

Keywords :   


Tag: data presentation

Data Needs Presentation 12-19-2017

2018-03-30 17:31:24| PortlandOnline

PDF Document, 1,256kbCategory: April 3, 2018

Tags: data presentation data presentation presentation data

 

MWESB Performance Data Presentation

2017-07-29 01:41:40| PortlandOnline

PDF Document, 169kbCategory: October

Tags: data performance presentation performance data

 
 

PHB MWESB Performance Data Presentation

2016-09-30 18:35:05| PortlandOnline

PDF Document, 169kbCategory: October

Tags: data performance presentation phb

 

PRESENTATION -- Preliminary Data Analysis and Best Practices

2015-12-11 23:24:58| PortlandOnline

PDF Document, 3,098kbCategory: Vision Zero Task Force Meeting #2: Goals & Policies (11/5/15)

Tags: best data analysis presentation

 

Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014

2014-09-29 11:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with data advanced early

 

Sites : [1] [2] [3] next »